Glucoside

Other Names

Alpha-glucosideBeta-glucosideGlucose glycosideGlycoside (glucose-based)O-glucosidePlant glycoside (glucose type)

Synopsis

Glucosides: A Comprehensive Encyclopedic Reference

1. Identity, Chemistry, and Classification

1.1 Nomenclature and Chemical Definition

Glucosides are a specific subclass of the broader family of compounds known as glycosides. In chemistry, "glucoside" is the generic name of an extensive group of substances characterized by the property of yielding a sugar — more commonly glucose — when hydrolysed by chemical means or decomposed by a ferment or enzyme. More precisely, glycosides are molecules made up of a carbohydrate (usually monosaccharides or sugars) and a nonglucidic compound. The sugar portion of most naturally occurring glycosides is glucose and, accordingly, these glycosides are known specifically as glucosides.

Structurally, similar to all glycosides is a construction consisting of two parts: an aglycone (genin) unit, which is mainly lipophilic, and a glycone unit which is hydrophilic and composed of one or more sugar components. The aglycone is bound to the anomeric carbon (C-1 carbon) of the glycone. The linkage between the sugar and the aglycone is a hemiacetal between the aldehyde or keto group of the sugar and an alcoholic or phenolic hydroxyl group of the aglycone.

Although glucose is the commonest sugar present in glucosides, many are known which yield rhamnose or iso-dulcite; these may be termed pentosides. When the nonsugar part of a glycoside (the aglycon) is a phenol or alcohol, the compound is known, respectively, as an aryl glycoside or an alkyl glycoside.

1.2 Classification by Aglycone Type

Therapeutic glucosides can be classified into many compounds based on the sugar moiety, chains/saccharide units, glycosidic linkages, and aglycones. Among many classes, the widely used pharmacological classification is based on the aglycones linked to the glycoside molecule. Based on these non-sugar moieties, plant glycosides are further classified into twelve different types of glycosides along with the recent discovery of novel cannabinoid glycosides.

They are called alcoholic, anthraquinone, coumarin, chromone, cyanogenic, flavonoid, phenolic, cardiac, saponin, thio, steviol, iridoid, and cannabinoid glycosides. Key examples of each type widely encountered in dietary supplements and natural health products include:

Flavonoid glucosides: There are a number of glucosides found in natural phenols and polyphenols, as, for example, in the flavonoids chemical family. These include quercetin glucosides, rutin, and anthocyanins.
Phenolic glucosides: Phenols and their glycosides are distributed widely in the plant kingdom. Examples include salicin and populin (Salicaceae family), arbutin (Ericaceae and Rosaceae family), and coniferin (Coniferae family).
Cardiac glycosides: Cardiac glycosides represent a family of compounds that are derived from the foxglove plant (Digitalis purpurea).
Anthocyanin glucosides: The anthocyanidins usually contain one sugar moiety, which is commonly conjugated to the C3 hydroxyl group in the C-ring, making them glycosides. Sugar moieties such as glucose, galactose, rhamnose, arabinose, and xylose are commonly found in anthocyanins.

1.3 Biological Role in Plants

Glycosides represent a large group of secondary metabolic products derived from plants, demonstrating several known functions, including growth regulation, allelopathy (inhibition of other plant growth), and defense mechanisms against damage induced by herbivores and pathogens. Many plants store chemicals in the form of inactive glycosides, which can be activated by enzyme hydrolysis. For this reason, most glycosides can be classified as prodrugs, as they remain inactive until they are hydrolyzed, leading to the release of the aglycone, the active constituent.

1.4 Natural Sources

Glucosides are extraordinarily widespread in the plant kingdom. Major dietary and botanical sources include:

Quercetin glucosides: Quercetin is found in many foods, such as green tea, cranberry, apple, onions, asparagus, radish leaves, buckwheat, blueberry, broccoli, and coriander.
Salicin: D(-)-Salicin, an organic compound with the chemical formula C₁₃H₁₈O₇ extracted from white willow bark, is a glycoside compound. White willow bark extracts are standardized to salicin, which has been used for thousands of years as an anti-inflammatory, purgative, and analgesic. D(-)-Salicin has been found to be widely present in the bark and leaves of a wide range of willow and poplar plants, e.g., purple willow bark contains up to 30% salicin.
Arbutin: Arbutin is a natural β-D-glucopyranoside derivative of hydroquinone, extracted from Uva ursi folium. The synthetic α isomer is mainly used as a skin brightening agent, while β-arbutin occurs naturally, for instance in bearberry, and is used in drugs for treatment of lower urinary tract infections and as a food supplement.
Anthocyanin glucosides: Six anthocyanidins — namely cyanidin, pelargonidin, delphinidin, petunidin, peonidin, and malvidin — are particularly prevalent in nature and account for approximately 90% of all anthocyanins. These occur as glucosides in berries, red grapes, and other deeply colored fruits and vegetables.
Glucosinolates (thioglucosides): Natural sources of thioglucosides include nasturtium (Tropaeolum majus L.) containing glucotropaeoline; black radish, high in glucoraphanin, 4-methoxybrassicin, glucobrassicin, and sinigrin; field mustard and broccoli with high levels of glucoraphanin; and horseradish rich in sinigrin.
Cardiac glycosides: Digitalis, digoxin, and digitoxin are cardiac glycosides that enhance myocardial contractility by inhibiting sodium-potassium ATPase. Originally derived from the purple foxglove flower (Digitalis purpurea), the cardiac glycosides have been used in clinical medicine for more than two centuries.

1.5 Common Forms and Preparations

Glucosides are encountered in numerous forms for dietary supplementation and clinical/pharmaceutical use:

Standardized plant extracts (e.g., willow bark extract standardized to salicin content)
Isolated or semi-purified glucoside compounds in capsule or tablet form
Topical preparations for skin-active glucosides such as arbutin
White willow bark extracts are commercially available in various grades and compositions, e.g., 15, 25, or 50 percent salicin.
Willow is available in various dosage forms, including tablets, capsules, powders, and liquids.
Quercetin may be supplied as its glycosides including rutin (quercetin-3-O-rutinoside), quercitrin (quercetin-3-rhamnoside), isoquercetin (quercetin-3-glucoside, also known as isoquercitrin), and alpha-glycosyl isoquercetin. The glycosides are preferred because of their greater water solubility and absorbability, and thus bioavailability, compared to quercetin itself.

2. Traditional and Historical Use

2.1 Ancient Origins

The use of glucoside-rich plants predates systematic chemical understanding by millennia. Over 3,500 years ago, bark from the willow tree was used as a pain reliever and an anti-inflammatory by Sumerians and Egyptians. In later years, it was used to ease the pain of childbirth in ancient Greece and to cure fevers.

The earliest historical records of herbs are found from the Sumerian civilization, where hundreds of medicinal plants including opium are listed on clay tablets, c. 3000 BC. The Ebers Papyrus from ancient Egypt, c. 1550 BC, describes over 850 plant medicines. Willow was among the herbs listed in these early Egyptian records.

Historically, white willow bark has been used for more than 2,000 years, initially in Egypt and Greece, then in China, Europe, North and South America, the Caribbean, and the Mediterranean.

2.2 Traditional Chinese Medicine

The first Chinese herbal book was the Shennong Bencaojing, compiled during the Han dynasty but dating back to a much earlier date, which was later augmented as the Yaoxing Lun (Treatise on the Nature of Medicinal Herbs) during the Tang dynasty. A great Chinese physician and naturalist, Li Shizen, wrote the pharmacopoeia Ben Ca Gang Mu, published in 1596. It contains 1,894 prescriptions and is still used as a reference and guide for research and teaching in China and several other communities. Many of the plant medicines documented in these texts are now known to be glucoside-rich. In China, over 100 traditional medicines contain extracts from toxic toads, including Liushen Pill, Chansu Pill, and Chan Su Analgesic Cream — preparations containing cardiac glycosides such as bufalin.

2.3 Ayurvedic Tradition

Many herbs and minerals used in Ayurveda were described by ancient Indian herbalists such as Charaka and Sushruta during the 1st millennium BC. Ayurveda, a system of medicine from India and surrounding areas, has an oral tradition that is at least 5,000 years old. The Charaka Samhita mentions over 300 herbs, many of which are still used in contemporary Ayurvedic practice.

2.4 Greek, Roman, and European Traditions

The Greek physician Dioscorides documented over 1,000 recipes for medicines using over 600 medicinal plants in De materia medica, c. 60 AD; this formed the basis of pharmacopoeias for some 1,500 years. Many of the plant remedies cataloged by Dioscorides — including willow bark — are now understood to derive their pharmacological activity from glucoside constituents.

Willow bark was used traditionally by herbalists for fever, headache, pain, and rheumatic complaints. In the late 19th century, the constituent salicylic acid was isolated from willow bark and went on to become the model for the development of aspirin (acetylsalicylic acid).

The therapeutic benefits of digitalis were first described by William Withering in 1785. Initially, digitalis was used to treat dropsy, which is an old term for edema. Subsequent investigations found that digitalis was most useful for edema caused by a weakened heart (i.e., heart failure).

3. Key Constituents and Active Compounds

3.1 Salicin (Phenolic Glucoside)

Salicin is a naturally occurring β-glucoside with antioxidant and anti-inflammatory properties predominantly derived from willow bark. The glycoside salicin, from which the body can split off salicylic acid, is thought to be the source of the anti-inflammatory and pain-relieving actions of willow. The analgesic actions of willow are typically slow to develop but may last longer than the effects of standard aspirin products. Important ingredients of willow bark include salicin and salicylic acid, salicortin, and fragilin (acetyl salicin), while the bark of poplars contains populin (benzoyl salicin).

3.2 Flavonoid Glucosides (Quercetin, Rutin, Isoquercitrin)

Quercetin is the major polyphenolic flavonoid that belongs to the class called flavanols. It occurs in many different forms, but the most abundant quercetin derivatives are glycosides and ethers, namely Quercetin 3-O-glycoside, Quercetin 3-sulfate, Quercetin 3-glucuronide, and Quercetin 3′-methylether. In plant-based foods, quercetin is mainly present in its glycoside form rather than its aglycone form.

Quercetin is metabolized into glycosides including rutin and hyperoside. Rutin (quercetin-3-O-rutinoside) is one of the most widely studied flavonoid glucosides, present in buckwheat, citrus peel, and many other foods.

3.3 Arbutin (Hydroquinone Glucoside)

Arbutin is a compound of hydroquinone and D-glucose. Arbutin's mechanism of action is based on the inhibition of both tyrosinase and 5,6-dihydroxyindole-2-carboxylic acid (DHICA) polymerase. In vivo, the glycosidic bond is hydrolysed, allowing the controlled release of hydroquinone.

3.4 Anthocyanin Glucosides

With the exception of 3-deoxyanthocyanins, anthocyanins exist almost exclusively in a glycosylated form. Their aglycone counterparts are not stable and are rarely found in nature. The most commonly studied anthocyanin glucosides include cyanidin-3-O-glucoside, malvidin-3-O-glucoside, and pelargonidin-3-O-glucoside.

3.5 Cardiac Glycosides (Digoxin, Digitoxin)

Cardiac glycosides, e.g., digitalis and digoxin, are naturally occurring compounds found in various plants and amphibians, characterized by a steroid ring, a lactone ring, and a sugar moiety. Digitalis spp. contain several cardiac glycosides including digitoxin, gitoxin, and lanatosides that inhibit sodium-potassium adenosinetriphosphatase (ATPase) activity.

3.6 Thioglucosides (Glucosinolates)

Glucosinolates (GLS) and their derivatives are secondary plant metabolites abundant in Brassicaceae. Due to the enzymatic reaction between GLS and myrosinase enzyme, characteristic compounds with a pungent taste are formed, used by plants to defend themselves against insect herbivores. These GLS derivatives have an important impact on human health, including anti-inflammation and anti-cancer effects.

4. Mechanisms of Action

4.1 Prodrug Activation and Enzymatic Hydrolysis

A defining biochemical feature of glucosides is their prodrug character. The breakdown of glycosidic linkages can be achieved by enzymes (such as β-glucosidases) or acids. Many plants store chemicals in the form of inactive glycosides, which can be activated by enzyme hydrolysis. For this reason, most glycosides can be classified as prodrugs, as they remain inactive until hydrolyzed, leading to the release of the aglycone, the active constituent.

4.2 Intestinal Absorption Pathways

Quercetin glycosides are known to be taken up in the small intestine via the sodium-dependent glucose transporter SGLT1. Following the ingestion of flavonoids, sugar moieties (as in quercetin-3-glucoside) are cleaved from the phenolic backbone in the small intestine and absorbed there. Enzymes such as lactase phlorizin hydrolase (LPH) at the enterocyte membrane, or β-glucosidase in the cytosol, hydrolyze glycosylated flavonoids and then aglycones enter epithelial cells by passive diffusion.

Almost all isoflavones (daidzein, genistein, and formononetin) exist as glucosides and therefore are not absorbed across enterocytes due to their high polarity and molecular weight. These flavonoids are present almost exclusively in plants from the Fabaceae family (soy, lentils, beans, and chickpeas). Their bioavailability requires conversion of glucosides into the bioactive aglycones via the action of intestinal β-glucosidases from small intestine bacteria (Lactobacillus, Bifidobacterium).

4.3 Gut Microbiota and Bioavailability

Dietary plant glucosides are phytochemicals whose bioactivity and bioavailability can be modified by glucoside hydrolase activity of intestinal microbiota through the release of aglycones. Bifidobacteria are gut commensals whose genomic potential indicates host-adaptation, as they possess a diverse set of glycosyl hydrolases giving access to a variety of dietary glycans. Several studies showed that the human gut microbiome can provide myrosinase activity that potentially can raise the beneficial effects of consumption of vegetables rich in glucosinolates.

For many drugs and their metabolites that are subject to conjugation to form sulfates, glucuronides, or glycosides, the bile provides a major route of excretion; once these conjugates come into contact with the gut microbiota, there is obvious potential for deconjugation to occur. The liberation of the aglycones by microbial enzymes enables their resorption (enterohepatic recycling) by the host and as such can increase overall bioavailability.

4.4 Anti-Inflammatory Mechanisms

Willow bark extract inhibits pro-inflammatory cytokines, such as tumor necrosis factor α (TNFα), cyclooxygenase-2 (COX-2), and the nuclear translocation of the transcription factor in proinflammatory activated monocytes, resulting in its anti-inflammatory effect.

Quercetin's anti-inflammatory properties involve inhibiting the production of inflammatory cytokines and enzymes, making it a potential therapeutic agent for various inflammatory conditions.

4.5 Antioxidant Mechanisms

Quercetin's strong antioxidant properties enable it to scavenge free radicals, reduce oxidative stress, and protect against cellular damage. Cyanidin and cyanidin 3-O-β-D-glucoside have shown a protective effect on DNA cleavage and a dose-dependent activity of scavenging free radicals.

4.6 Cardiac Glycoside Mechanism

Digitalis compounds are potent inhibitors of cellular Na⁺/K⁺-ATPase. This ion transport system moves sodium ions out of the cell and brings potassium ions into the cell. Inhibition of the Na⁺/K⁺-ATPase in vascular smooth muscle causes depolarization, which causes smooth muscle contraction and vasoconstriction.

4.7 Skin Depigmentation Mechanism (Arbutin)

The mechanism behind the whitening effects of arbutin revolves around its ability to inhibit the activity of tyrosinase, which plays a crucial role in the production of melanin — the pigment responsible for skin, hair, and eye color. Inhibition of tyrosinase decreases the amount of melanin produced by the melanocytes, leading to the depigmentation of the skin. Arbutin and monoester derivatives of arbutin have been shown to decrease the amount of melanin produced by melanocytes by inhibiting tyrosinase.

5. Scientific Evidence by Area of Use

5.1 Pain Relief and Anti-Inflammatory Activity (Salicin/Willow Bark)

Clinical Evidence — Moderate: As the precursor of aspirin, salicin cannot fully explain the activity of willow bark. A meta-analysis was conducted based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. PubMed, Scopus, EMBASE, Web of Science, Cochrane, and ClinicalTrials.gov were searched for randomized controlled trials (RCTs) describing the efficacy or adverse events of willow bark in patients with arthritis until April 12, 2023. The Cochrane ROB 2.0 and the GRADE system were used to evaluate study quality. The meta-analysis was carried out by the fixed-effects model and included five studies with six RCTs, consisting of 329 patients with arthritis. The results showed significant differences in pain relief and improvement in physical status for patients with arthritis between willow bark treatment and placebo groups.

Willow bark extract has comparable anti-inflammatory activities to higher doses of acetylsalicylic acid (ASA) and shows antinociceptive and antipyretic activities. Two 6-week, randomized, double-blind trials examined the efficacy of willow bark in treating outpatients with hip or knee osteoarthritis (N=127) and outpatients with active rheumatoid arthritis (N=26).

Although willow bark extracts are generally standardized to salicin, other ingredients in the extracts, including other salicylates as well as polyphenols and flavonoids, may also play prominent roles in the therapeutic actions. Under pharmacologically active doses, no adverse effects regarding the stomach mucosa were observed, in contrast to acetylsalicylic acid.

5.2 Cardiovascular Health (Flavonoid Glucosides)

Evidence Level — Epidemiological/Observational, some RCT data: A variety of human cohort studies and intervention studies support the idea that the intake of quercetin glycoside-rich plant foods such as onion helps to prevent CVD. Thus, quercetin glycoside-rich foods offer potential benefits in terms of cardiovascular health and possible clinical applications.

A case-control study of non-fatal acute myocardial infarction (AMI) reported that the risk of AMI was decreased by the consumption of one or more portions of onion per week. In addition, an Iranian cohort study with a 6-year follow-up period showed that a higher habitual intake of allium vegetables (i.e., garlic and onion) was associated with reduced risk of CVD outcomes. These observational studies strongly suggest the beneficial effects of onion and other quercetin glucoside-rich foods in terms of CVD prevention.

Large-scale intervention studies — namely the Iowa Women's Health study and the Danish Cancer and Health cohort study — showed that habitual flavonoid intake was inversely associated with all-cause and cardiovascular mortality. A plentiful intake of dietary flavonoids and flavonoid-rich foods appears to be associated with the prevention of CVD. Numerous in vitro and in vivo studies have proposed mechanisms for the prevention of CVD by flavonoids, such as the improvement of endothelial cell function, suppression of oxidized LDL accumulation, and anti-inflammatory effects.

Quercetin has cardiovascular benefits such as lowering blood pressure, reducing cholesterol levels, and improving endothelial function, making it a promising candidate for preventing and treating cardiovascular diseases. Evidence for these benefits has primarily come from in vitro experiments, animal studies, and epidemiological data; dedicated interventional RCT evidence in human populations remains limited.

5.3 Skin Depigmentation (Arbutin)

Evidence Level — Preliminary to moderate clinical evidence for topical use: In a human clinical trial, topical treatment with deoxyarbutin for 12 weeks resulted in a significant or slight reduction in overall skin lightness and improvement of solar lentigines in a population of light-skinned or dark-skinned individuals, respectively.

The skin lightening efficacy of arbutin alone or in combination with other active ingredients has been clinically evaluated. Combined therapy with arbutin and laser could give enhanced depigmenting efficacy.

A 2025 prospective interventional study (efficacy and safety of topical formulation of trihydroxybenzoic acid glucoside 10% and α-arbutin 2%, twice daily, plus sunscreen once daily in Indian females aged 18–45 years, n=124, with Fitzpatrick skin type III–IV and facial dark spots or melasma) demonstrated measurable reductions in melanin content over a 90-day regimen.

The European Medicines Agency (EMA) concluded that, based on traditional use, the effectiveness of uva ursi extracts was plausible and that their use was safe. However, the EMA noted that clinical studies allowing a final assessment of efficacy were lacking.

5.4 Antioxidant and Anti-Inflammatory Activity (Anthocyanin Glucosides)

Evidence Level — Largely in vitro and animal; clinical evidence emerging: Consumption of anthocyanins (ACNs), due to their antioxidant, anti-inflammatory, and anti-apoptotic effects, has been proposed for the prevention and treatment of several different diseases and conditions. ACNs are recognized as one of the leading nutraceuticals for prolonging health benefits through the attenuation of oxidative stress and inflammatory or age-related diseases.

Research on the antioxidant, anti-inflammatory, anticancer, and neuroprotective effects of anthocyanins has been critically reviewed. Cyanidin and cyanidin 3-O-β-D-glucoside have shown a protective effect on DNA cleavage and a dose-dependent activity of scavenging free radicals.

Increased consumption of ACNs has the potential to attenuate the damage ensuing from oxidative stress and inflammation, enhance cardiometabolic health, and delay symptoms in predisposed neuropathology. A myriad of evidence supports ACN consumption as complementary or standalone treatment strategies for non-communicable diseases including obesity, diabetes, cardiovascular disease, and neurodegenerative diseases, as well as for the modulation of gut bacteria and bone metabolism.

5.5 Metabolic Health / Diabetes (Anthocyanin Glucosides)

Evidence Level — Preclinical strong; human RCT evidence growing: Anthocyanins have been shown to have positive effects by inhibiting digestive enzymes, enhancing insulin secretion, reducing apoptosis, promoting proliferation of pancreatic β-cells, and improving hyperglycemia through regulation of glucose metabolism in hepatocytes. Furthermore, they may decrease insulin resistance, inflammation, and oxidative stress in muscle and fat, while enhancing glucose uptake in both skeletal muscle and white adipose tissue. ACNs possess antioxidant properties that can effectively inhibit the activation of pro-inflammatory pathways, which are often exacerbated by oxidative stress under diabetes conditions.

Treatment with one of the most widely distributed ACNs, cyanidin-3-O-glucoside, accelerated the growth of blood vessels and collagen, showing that anthocyanins help diabetic wounds heal.

5.6 Bone Health (Quercetin Glucosides — Rutin, Hyperoside)

Evidence Level — In vitro only; clinical evidence absent: Administration of rutin (≥25 µM) and hyperoside (≥5 µM) resulted in higher mineral content in human osteoblast (Saos2) cells, accompanied by higher alkaline phosphatase activity with no cell toxicity. The expression of osteopontin, sclerostin, TNFα, and IL-6 — known stimuli for decreasing osteoblast activity — were reduced with the addition of rutin or hyperoside. However, rutin and hyperoside require supraphysiological levels, when administered individually, to positively influence osteoblast activity. No clinical human trials have been conducted to confirm this effect.

5.7 Cardiovascular Pharmacotherapy (Cardiac Glycosides)

Evidence Level — Well-established clinical evidence; narrow therapeutic window: Digitalis and its derivatives such as digoxin and digitoxin are cardiac glycosides used typically in the therapy of congestive heart failure and atrial fibrillation. Digoxin, derived from the foxglove plant (Digitalis lanata), has been used in cardiovascular medicine since the 18th century and continues to play an essential role in the contemporary management of appropriately selected patients with heart failure and atrial fibrillation. However, once used as first-line agents for congestive heart failure and atrial fibrillation, cardiac glycosides have been replaced by agents that are better tolerated and have been shown to improve long-term survival, such as ACE inhibitors and beta-blockers.

6. Body Systems and Health Areas Associated with Glucosides

Cardiovascular system: Flavonoid glucosides (antioxidant, endothelial protection, anti-atherosclerotic effects); cardiac glycosides (heart failure, arrhythmia management).
Musculoskeletal/Pain: Salicin and willow bark glucosides (analgesia, anti-inflammatory effects in arthritis and low back pain).
Integumentary system (skin): Arbutin (tyrosinase inhibition, hyperpigmentation management).
Urinary tract: Arbutin, which occurs in bearberry along with methyl arbutin, hydrolyses to hydroquinone and glucose. Pharmacologically it acts as a urinary antiseptic and diuretic.
Metabolic/Endocrine system: Anthocyanin glucosides and isoflavone glucosides (glucose metabolism, insulin sensitivity, antidiabetic effects).
Immune and inflammatory system: Multiple flavonoid glucosides (cytokine modulation, NF-κB pathway inhibition, COX-2 inhibition).
Gastrointestinal system: Glucosides interact significantly with gut microbiota and are metabolized by intestinal β-glucosidases, influencing microbial ecology.
Neurological system: Increased consumption of ACNs has the potential to delay symptoms in predisposed neuropathology.

7. Dosage Forms and Reported Dosages

Reported dosages cited in scientific literature are as follows (noted only as stated in the source):

Willow bark extract (standardized to salicin): A daily dose of 1,572 mg willow bark extract of a proprietary preparation (Assalix; standardized to 15.2% salicin, i.e., 240 mg salicin per day) was significantly superior to placebo in patients with osteoarthritis of the hip and knee and in patients with exacerbations of chronic low back pain. Clinical studies evaluating the analgesic effects of willow bark (e.g., for lower back pain, dysmenorrhea) used extracts delivering daily salicin doses of 120 to 240 mg.
Arbutin (topical): A topical formulation of trihydroxybenzoic acid glucoside 10% and α-arbutin 2% was assessed twice daily alongside a once-daily sunscreen regimen in a clinical study.
Rutin/Hyperoside (in vitro cell studies): Administration of rutin (≥25 µM) and hyperoside (≥5 µM) resulted in higher mineral content in human osteoblast (Saos2) cells. Note: these are in vitro concentrations, not oral dosages.
Glucosanol (a glucoside-based supplement): In a registered clinical trial (NCT02930681), Glucosanol was studied at 1,000 mg and 2,000 mg (four capsules of 500 mg each), administered 30 minutes before test meals in 24 overweight subjects to assess effects on post-prandial glucose levels.

8. Safety Considerations and Drug Interactions

8.1 Salicin and Willow Bark

Adverse effects of willow bark appear to be minimal compared to non-steroidal anti-inflammatory drugs including aspirin. The primary cause for concern may relate to allergic reactions in salicylate-sensitive individuals.

People with gastritis, stomach ulcers, diabetes, asthma, or haemophilia should avoid using willow bark extract. Willow bark may interact with anticoagulants (increasing the risk of bleeding), beta-blockers and diuretics (decreasing the effect of the drug), and NSAIDs (increasing the risk of stomach bleeding). White willow bark extract should not be used in children under the age of 16, as it may cause Reye syndrome.

Both salicin and aspirin produce anti-inflammatory effects after they have been converted to salicylic acid in the body. Taking salicylates with beta-adrenergic blocking drugs has resulted in decreased absorption of the drugs.

8.2 Arbutin

Both isomers of arbutin (α and β) can be harmful at high concentrations. Compared with hydroquinone, arbutin seems to be less cytotoxic. The EMA acknowledges the plausibility of its traditional use for urinary tract applications but notes that conclusive clinical trial data are limited. Arbutin has poor skin penetration due to its hydrophilic nature and relatively large molecular size. It is generally considered safe for topical use with a lower incidence of irritation and sensitization.

8.3 Cardiac Glycosides (Digoxin/Digitoxin)

Digoxin's narrow therapeutic window makes it susceptible to toxicity, necessitating careful dosing based on patient-specific factors, including renal function and drug interactions. Plasma concentrations above 2.0 ng/ml can lead to digitalis toxicity, which is frequently manifested as arrhythmias, some of which may be life-threatening. If toxicity occurs with digoxin, it may take several days for the plasma concentrations to fall to safe levels because of the long half-life.

The Class IA antiarrhythmic quinidine competes with digoxin for binding sites and depresses renal clearance of digoxin, increasing digoxin levels and potentially producing toxicity. Similar interactions occur with calcium-channel blockers and non-steroidal anti-inflammatory drugs. Other drugs that interact with digoxin are amiodarone (Class III antiarrhythmic) and beta-blockers.

Diuretics can indirectly interact with digoxin because of their potential for decreasing plasma potassium levels (i.e., producing hypokalemia). Hypokalemia results in increased digoxin binding to the Na⁺/K⁺-ATPase and thereby enhances digoxin's therapeutic and toxic effects. Hypercalcemia enhances digitalis-induced increases in intracellular calcium, which can lead to calcium overload and increased susceptibility to digoxin-induced arrhythmias. Hypomagnesemia also sensitizes the heart to digoxin-induced arrhythmias.

8.4 Glucosinolates

Most food-processing treatments inactivate the myrosinase (MYR) enzyme, hampering the production of bioactive isothiocyanates. The bioactivity of glucosinolates is thus highly preparation-dependent, with cooking methods substantially affecting the conversion to active compounds.

8.5 General Considerations Across Glucoside Classes

Glucosides are structurally diverse and, given their proven bioactivities and traditional use, they are of great importance to the regime of pharmacognosy; still, there remains much to be elucidated on their roles and properties.

Inter-individual variation in gut microbiota composition is a significant modulator of glucoside bioavailability. Beta-glucosidase activity of bifidobacteria is species specific and most prevalent in species occurring in human adults and animal hosts. Utilization and fermentation profiles of plant glucosides differed between strains and might provide a competitive benefit enabling the intestinal use of dietary plant glucosides as energy sources.

References

Health Conditions

Health conditions that Glucoside may help support.

No conditions available.

Body Systems

Body systems that Glucoside may help support.

No body systems available.